693-P: Daily Meal Size Variation Does Not Affect Glucose Control in Adult T1D Patients Under Closed-Loop Equipped with DBLG1 System

The aim of this study is to assess the effect of meal size on glycemic control for T1D patients equipped with Diabeloop’s DBLG1 Closed Loop System[1], based on data from DBLG1 System Commercial Launch. The Soft Launch dataset comprises 34 adult type 1 diabetes patients with an average duration of 206 days for a total of 7011 days of treatment. Only days with ≥70% available CGM data were included in the analysis (97.3 % of total). To assess the effect of patient meal size (the daily sum of CHO declared by each patient on his device) on glycemic control, we compute the difference in percentage point between patient daily value and patient daily mean value of both Time In Range (TIR) (Figure 1) and Time In Hyperglycemia (TIHYPER) and plot it against each daily CarboHydrates (CHO) as a percentage of the mean daily CHO for this patient. This way we can observe the effect of bigger and smaller than average meals and determine if they tend to increase or decrease TIR and TIHYPER. As presented on Figure 1, days with increased CHO consumption are not linked to a drop in TIR. We observe no correlation between the TIR and the daily amount of CHO ingested (r=0.01), nor between the TIHYPER and the daily amount of CHO ingested (r=-0.12). In conclusion, Diabeloop’s DBLG1 Closed Loop System’s performance is not altered by the variations in daily amount of carbohydrates ingested by T1D patients. Disclosure P. Gimenez: Employee; Self; Diabeloop SA. S. Lachal: Employee; Self; Diabeloop SA. Y. Tourki: Employee; Self; Diabeloop SA. S. Franc: Advisory Panel; Self; Diabeloop SA, Board Member; Self; Novo Nordisk, Other Relationship; Self; Abbott Diabetes, Research Support; Self; Merck Sharp & Dohme Corp., Stock/Shareholder; Self; Diabeloop SA. C. Amadou: Other Relationship; Self; AstraZeneca, Diabeloop SA, Lilly Diabetes. A. Penfornis: Board Member; Self; Medtrum Technologies, Merck Sharp & Dohme Corp., Mundipharma International, Sanofi-Aventis, Other Relationship; Self; Medtrum Technologies, Speaker’s Bureau; Self; Amgen Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi-Aventis. G. Charpentier: Other Relationship; Self; Diabeloop. P. Y. Benhamou: Consultant; Self; Diabeloop SA, Eli Lilly and Company, Insulet Corporation, Other Relationship; Self; Abbott Diabetes.